Rationale and design of study of dapagliflozin versus sitagliptin treatment efficacy on prevention of cardiovascular risk factors in type 2 diabetes patients: the DIVERSITY-CVR study

BACKGROUND: Recent studies reported that sodium glucose cotransporter 2 (SGLT2) inhibitors reduced the cardiovascular morbidity and mortality in patients with type 2 diabetes mellitus (T2DM) compared to placebo in contrast to no reduction with dipeptidyl peptidase 4 (DPP4) inhibitors. However, there...

Descripción completa

Detalles Bibliográficos
Autores principales: Shigiyama, Fumika, Kumashiro, Naoki, Fuchigami, Ayako, Hirose, Takahisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5996551/
https://www.ncbi.nlm.nih.gov/pubmed/29895330
http://dx.doi.org/10.1186/s12933-018-0730-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5996551/
https://www.ncbi.nlm.nih.gov/pubmed/29895330
http://dx.doi.org/10.1186/s12933-018-0730-z

Ejemplares similares